The Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States (Perinatal Guidelines) were updated on April 29, 2016. In this revision:
- Table 7: Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy was revised.
- The abacavir, etravirine, and didanosine sections were updated to include new data and publications, including Food and Drug Administration label updates.
- The amprenavir, delavirdine, and zalcitabine sections were removed from the guidelines as the drugs are no longer available in the United States. Additional information on these drugs can be found in the archived Perinatal Guidelines.
Additionally, the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents were updated on May 3, 2016. In this revision, the Bacterial Enteric Infections section was updated to include new information on the growing issue of antibiotic resistance among enteric bacteria, as well as updated information on the treatment of enteric infections, including in pregnant women.